Outlook Therapeutics, Inc.
NASDAQ:OTLKBiotechnology
-$0.10 today
- Market cap
- $99.30M
- Beta
- 0.98
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$0.74
Volume 4.42M
Average 17.46M
OTLK Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Outlook Therapeutics, Inc.NASDAQ: OTLK
Research & Development · Q2 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q2 FY2026 research & development of $4.5M rose 2.1% year over year, ahead of the -43.8% change in trailing-twelve-month research & development. Sequentially, it rose 23.8% from the prior quarter. Over 3 fiscal years it compounded at +8527.1% a year.
Context
- Research & development amounted to 1922884116.8% of revenue in FY2025.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +2.1% holds above the trailing-twelve-month pace of -43.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 27.18T USD
- Year-over-year change
- +65082964.0%
- 4-year CAGR
- +2790.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 27.18T | +65082964.0% |
| FY2024 | 2024-09-30 | 41.76M | +57.9% |
| FY2023 | 2023-09-30 | 26.45M | -37.5% |
| FY2022 | 2022-09-30 | 42.33M | +8.7% |
| FY2021 | 2021-09-30 | 38.96M | — |
Research & Development vs competitors
How OTLK compares with its peers on the latest reported figures
- OTLK's LTM Mar 2026 research & development of $21.25M is the 5th highest of the 9 companies compared; the peer median is $24.8M.
- Its year-over-year change of -43.8% is the 7th highest of 9, against a peer median of -21.6%.
- Research & development amounts to 6378.2% of revenue for OTLK, versus a peer median of 133.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | LTM Mar 2026 | $16.37B | +432309.4% | +1606.6% | — |
| LTM Mar 2026 | $83.18M | -24.7% | -0.5% | — | |
| LTM Mar 2026 | $36.03M | +4.0% | -0.7% | 110.1% | |
| LTM Jun 2026 | $32.91M | -39.6% | -5.9% | 156.7% | |
| LTM Mar 2026 | $21.25M | -43.8% | +8527.1% | 6378.2% | |
| LTM Mar 2026 | $16.69M | -64.4% | -17.8% | — | |
| LTM Mar 2026 | $9.91M | -70.5% | -30.1% | — | |
| LTM Mar 2026 | $4.28M | -18.5% | -39.5% | 186.8% | |
| LTM Mar 2026 | $1.43M | -13.1% | +294.0% | 100.9% | |
| Peer median (excluding OTLK) | $24.8M | -21.6% | -3.3% | 133.4% | |
Competitors are the stored peer set for OTLK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 1.41M |
| Cost of Revenue | 262.14K | 204.69K | 44.19K | 113.86K | 756.33K |
| Gross Profit | (262.14K) | (204.69K) | (44.19K) | (113.86K) | 657.21K |
| Gross Margin | — | — | — | — | 46.5% |
| Research & Development | 38.96M | 42.33M | 26.45M | 41.76M | 27.18T |
| Selling, General & Admin | 12.77M | 20.74M | 26.67M | 29.94M | 39.94M |
| Operating Expenses | 51.73M | 62.87M | 53.13M | 71.7M | 67.72M |
| Depreciation & Amortization | 262.14K | 204.69K | 44.19K | 113.86K | 117.05K |
| EBITDA | (51.51M) | (64.36M) | (57.38M) | (72.09M) | (63.58M) |
| EBITDA Margin | — | — | — | — | -4497.7% |
| Operating Income | (51.73M) | (63.07M) | (53.13M) | (71.7M) | (67.06M) |
| Operating Margin | — | — | — | — | -4744.3% |
| Interest Income | 0 | 0 | 0 | 906.15K | 89.74K |
| Interest Expense | 936.13K | 1.49M | 1.56M | 3.16M | 283.13K |
| Other Income / Expenses | (1.43M) | (2.98M) | (5.85M) | (3.66M) | 3.08M |
| Income Before Tax | (53.16M) | (66.05M) | (58.98M) | (75.36M) | (63.98M) |
| Pre-Tax Margin | — | — | — | — | -4526.0% |
| Income Tax Expense | 2K | 2.8K | 2.8K | 2.8K | (1.55M) |
| Net Income | (53.16M) | (66.05M) | (58.98M) | (75.37M) | (62.42M) |
| Net Margin | — | — | — | — | -4416.2% |
| EPS (Basic) | (6.96) | (6.23) | (4.72) | (4.06) | (1.79) |
| EPS (Diluted) | (6.96) | (6.23) | (4.72) | (4.06) | (1.79) |
| Weighted Avg Shares | 7.63M | 10.6M | 12.51M | 18.55M | 34.8M |
| Weighted Avg Shares (Diluted) | 7.63M | 10.6M | 12.51M | 18.55M | 25.48M |
Outlook Therapeutics, Inc.
NASDAQ:OTLK
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.